Semiconductor-metal-organic framework (MOF) hybrid photocatalysts have attracted increasing attention because of their enhanced photocatalytic activity. However, the effect of the interface reaction between semiconductor and MOFs is rarely studied. In this work, we studied the synthesis and photocatalytic activity of zeolitic imidazolate framework-8 (ZIF-8) decorated electrostatic spinning TiO2 nanofibers (TiO2 ESNFs). TiO2/ZIF-8 hybrid photocatalysts were prepared via a facile sonochemical route. It was crucial that the ZIF-8 was assembled homogeneously on the surface of TiO2 ESNFs and formed a N-Ti-O bond under sonochemical treatment, which may result in reducing recombination of the electron-hole pairs. The chemically bonded TiO2/ZIF-8 nanocomposites displayed excellent performance of thermal stability, controllable crystallinity, and great enhancement of photocatalytic activity in Rhodamine B (Rh B) photodegradation. Furthermore, the UV-vis light adsorption spectra of TiO2/ZIF-8 nanocomposites showed that the ZIF-8 photosensitizer extended the spectral response of TiO2 to the visible region. The new strategy reported here can enrich the method for designing new semiconductor-MOF hybrid photocatalysts.

Vasorin (VASN) is a type I transmembrane protein that plays important roles in tumor development and vasculogenesis. In this paper, we showed that VASN could be a key mediator of communication between tumor cells and endothelial cells. We confirmed for the first time that HepG2-derived VASN can be transferred to human umbilical vein endothelial cells (HUVECs) via receptor mediated endocytosis of exosomes, at least in part through HSPGs. The HepG2-derived VASN containing exosomes promote migration of recipient HUVECs cells. Our results identify a novel pathway by which a functional protein expressed in tumor cells affects the biological fate of endothelial cells via exosomes.

No abstract

We report a new biomarker of hepatocarcinoma, vasorin (VASN), screened by a subtractive EMSA-SELEX strategy from AFP negative serum of hepatocellular carcinoma (HCC) patients with extrahepatic metastases. VASN was verified to be highly expressed in sera of 100 cases of HCC patients compared with 97 cases of normal persons and 129 cases of hepatitis patients. Further validation by Q-PCR, IFA and Western blot showed higher expression of VASN at mRNA and protein levels in HCC cell lines and HCC tissues than in normal controls. RNA interference and forced overexpression assays verified that VASN promotes cell proliferation and migration and inhibits apoptosis. Down-regulation of microRNA miR145 and miR146a is an important mechanism leading to high expression of VASN. Conclusion: As a membrane protein and/or as free protein, VASN may be an effective target for biological treatment of liver cancer and is a potential biomarker for HCC diagnosis. Small molecular nucleotides targeting VASN are promising biological therapies to HCC.

No abstract